[Biomarkers for the diagnosis and management of heart failure: natriuretic peptides]

Area of Science:

• Cardiovascular Medicine
• Biomarker Discovery

Background:

• Heart failure (HF) is a significant cause of morbidity and mortality, often resulting from various cardiovascular diseases.
• Early diagnosis and prompt treatment are crucial for improving the natural history of HF patients.
• Circulating biomarkers offer insights into HF pathogenesis, aiding clinical diagnosis and management.

Purpose of the Study:

• To review the role of natriuretic peptides in the diagnosis, risk stratification, and management of heart failure.
• To explore the utility of B-type natriuretic peptides (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) in HF.

Main Methods:

• Literature review of studies investigating natriuretic peptides in heart failure.
• Analysis of biomarker validation for HF diagnosis and risk assessment.
• Evaluation of evidence for natriuretic peptides in HF screening and therapy guidance.

Main Results:

• B-type natriuretic peptides are validated tools for diagnosing HF and stratifying patient risk.
• Natriuretic peptides show promise for screening at-risk populations and guiding preventive measures.
• Evidence regarding the use of natriuretic peptides to guide HF therapy remains conflicting.

Conclusions:

• Natriuretic peptides are valuable biomarkers in cardiovascular medicine, particularly for heart failure.
• BNP and NT-proBNP facilitate early HF diagnosis, risk stratification, and preventive interventions.
• Further research is needed to clarify the role of natriuretic peptides in guiding HF therapy.